文献速递慢阻肺

Notch信号通路对慢性阻塞性肺疾病免疫失衡的影响及机制

[Effects and mechanisms of Notch signaling pathway on immune imbalance in chronic obstructive pulmonary disease].
PubMed 文献 · Zhonghua Jie He He Hu Xi Za Zhi · 2016-01-01

结果显示COPD小鼠脾源性Th1、Th17、Treg细胞比例及Th1/Th2比值均显著升高,Notch1及下游Hes1 mRNA和蛋白表达显著增加,GSI可部分抑制上述表达并降低Th1和Th17细胞比例。结论提示Notch信号通路参与COPD小鼠免疫紊乱。

要点

  • COPD小鼠存在Th1、Th17、Treg细胞比例升高及Th1/Th2、Th17/Treg比值升高的T淋巴细胞亚群失衡。
  • COPD小鼠脾T细胞Notch1及下游Hes1 mRNA和蛋白表达显著增加,且与Th1、Th17正相关、与Th2、Treg负相关。
  • γ分泌酶抑制剂可部分抑制Notch1、Hes1表达及Th1、Th17细胞,提示Notch通路参与COPD免疫失衡。

核心结论

  • COPD小鼠存在T淋巴细胞亚群失衡,表现为Th1、Th17促炎细胞增加。
  • COPD小鼠Notch1及其下游Hes1 mRNA和蛋白水平升高,并与T淋巴细胞亚群失衡相关。
  • GSI可部分抑制Notch1、Hes1表达及Th1和Th17细胞,提示Notch信号通路参与COPD小鼠免疫紊乱。

研究设计与样本

  • 采用香烟烟雾暴露建立COPD模型,经尼龙毛柱过滤富集T细胞。
  • 用流式细胞术检测脾源性T淋巴细胞亚群比例,用RT-PCR和Western blot检测脾T细胞Notch1及下游Hes1 mRNA和蛋白表达。

主要发现

  • COPD小鼠CD4+T细胞中Th1、Th17和Treg细胞百分比分别为(13.20±0.95)%、(10.22±0.45)%、(0.41±0.09)%,均显著高于健康对照组的(8.07±0.44)%、(5.98±0.26)%、(0.26±0.05)%(均P<0.01)。
  • COPD GSI组小鼠Th1和Th17细胞比例分别为(9.48±0.66)%和(7.70±0.39)%,均较COPD组显著降低(均P<0.01)。
  • COPD组Th1/Th2比值为18.70±4.12,显著高于健康对照组的12.63±1.91(P<0.01);COPD组Th17和Treg占CD4+T细胞百分比分别增加71%和58%;GSI降低Th1/Th2和Th17/Treg比值(均P<0.01)。
  • COPD小鼠Notch1受体及下游Hes1 mRNA表达分别为(5.15±0.77)和(1.92±0.32),蛋白表达分别为(0.85±0.04)和(0.16±0.02),均显著高于健康组[(1.00±0.00, 1.00±0.00)和(0.17±0.01, 0.09±0.01)](均P<0.01);GSI显著抑制Notch1及Hes1 mRNA和蛋白表达(均P<0.01)。
  • COPD组Notch1和Hes1 mRNA及蛋白表达与Th1和Th17细胞正相关,与Th2和Treg细胞负相关(均P<0.05)。

临床怎么用

  • 该研究为动物实验,Notch信号通路作为COPD免疫失衡干预靶点的价值尚需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the role of Notch signaling pathway on immune imbalance in chronic obstructive pulmonary disease (COPD). Methods: Thirty BALB/c mice were randomly assigned into the healthy control group, COPD group, and COPD Gamma secretase inhibitors (GSI) group. Cigarette smoke exposure was used to establish the COPD model. T cells were enriched by filtering through nylon wool columns. The proportion of spleen-derived T-lymphocyte subsets was detected by flow cytometry. Real-time quantitative polymerase chain reaction (RT-PCR) and Western blot (WB) were used to detect the expression of splenic T cells' Notch1 and its downstream Hes1 mRNA and protein respectively. Results: The percentage of Th1, Th17 and Treg cells in CD4+T cells of COPD mice (13.20±0.95, 10.22±0.45, 0.41±0.09)% were significantly increased compared with the healthy control group (8.07±0.44, 5.98±0.26, 0.26±0.05)%(all P<0.01). The proportion of Th1 and Th17 cells in COPD GSI group mice (9.48 ± 0.66, 7.70 ±0.39)% were significantly reduced compared with COPD group (all P<0.01). Ratio of Th1/Th2 in COPD group (18.70±4.12) was significantly increased compared with the healthy control group (12.63±1.91) (P<0.01), the percentage of Th17 and Treg in CD4+ T cell increased 71% and 58% respectively. GSI decreased the ratios of Th1/Th2 and Th17/Treg (all P<0.01). Notch1 receptor and its downstream Hes1 mRNA expression (5.15±0.77, 1.92±0.32) and protein expression (0.85±0.04, 0.16±0.02) of COPD mice were significantly increased compared with the healthy group respectively [(1.00 ± 0.00, 1.00 ± 0.00) and (0.17±0.01, 0.09±0.01)] (all P<0.01). GSI significantly inhibited the expression of mRNA and protein in Notch1 and its downstream Hes1 (all P<0.01). Notch1 and Hes1 mRNA and protein expressions were correlated positively with Th1 and Th17 cells and negatively correlated with Th2 and Treg cells in COPD group(all P<0.05). Conclusion: In COPD mice, there was T-lymphocyte subsets imbalance, such as the increased of Th1, Th17 proinflammatory cells, Notch1 and its downstream Hes1 mRNA and protein levels were increased, and was associated with T-lymphocyte subsets imbalance. GSI could partially inhibit Notch1, Hes1 expression and Th1 and Th17 cells, and thus Notch signaling pathway was involved in the immune disorder of COPD mice.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yang XN, Liu XJ, Zhao LT, et al. [Effects and mechanisms of Notch signaling pathway on immune imbalance in chronic obstructive pulmonary disease]. Zhonghua Jie He He Hu Xi Za Zhi. 2016. PMID: 27852366. doi:10.3760/cma.j.issn.1001-0939.2016.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。